•Company expects to initiate pivotal Phase III clinical trial by year-end 2017; will take approximately 9-12 months to complete
Soleno Therapeutics, Inc. (Soleno) is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is currently advancing its lead candidate, DCCR, a once-daily oral tablet for the treatment of PWS, into a Phase III clinical development program at the end of 2017.
Market Opportunity for PWS is Substantial.
While the lack of approved treatments for PWS alone make it difficult to assess the market, sales of Pfizer’s (NYSE: PFE) Genotrop in (somatropin) can provide some insight despite being indicate for PWS, in addition to, growth failure due to growth hormone deficiency(GHD),Turner syndrome,idiopathic short stature,and small for gestational age.This product achieved its highest revenue in 2008,with worldwide sales of approximately $900 million.While somatropin has been proven to improve growth and body composition, it does not affect the key disease component of hyperphagia and use is associated with substantial risk. Soleno is developing DCCR for the treatment of PWS,to help address the unmet need of this patient population. To assess the potential of DCCR for PWS, we performed a scenario analysis, which indicates that annual sales could be in the range of $1.1 billion given a moderate price point and 50% market penetrance.
weak hands step to the side and miss out
Buy some shares Phil, before we are back to .87
Buy some shares Phil
Title of #$%$ even this ..... the biopharm is just a scam !!!
Any more good news to drive SP higher or down it will go?
any idea besides 2H2017, when Phase 3 trials will begin?
And so the slow descend to .87 continues until years end when we can only hope Keytruda will be good for BL8040
If not, there is nothing for the next 18 months that will help bolster the share price
IL SETTORE BIO è SOLO UNA TRUFFA PER RUBARE SOLDI!!!!
Right now I just want to see 10 days above $1 and then I think we'll break a resistance point and hopefully end up around 1.25 or 1.30 (dreaming probably) after the positive earnings come out
Phil - You must be ready to resign by now? You suk and must totally feel inept watching the market soar higher while BLRX remains in the dumper
Be a man Phil you waste and buy some shares!
In the short-term BLRX does not seem to be like a good trade. This is so frustrating trying to find trade ideas. I've subscribed to some email newsletters which helps me with new stock ideas. awesom_sto-cks is the one i like best.
Check out OXIS, about to run hard. New management from Pfizer and Chase Pharma. Do your dd.
Check out OMER value. BLRX does not show any progress of its pipeline of drug candidates since 2012, which is the only weak spot I can tell.
Lookn' to buy in 1.10 range or lower. Seems to have a good story to it. Results by end of year or early next year + new capital with strike price in $2 range + low cash burn rate.
Regurgitated info by our illustrious CEO, Phildo. Buy some shares Phildo